• ImmuneOncia Therapeutics faces designation as a disclosure violator under an Oct. 28, 2026, notice; a decision is due Nov. 20, 2026.
• Late disclosures concerned clinical trial amendment application on July 1 and approval on Aug. 4; both disclosed Sept. 14, 2026.
• Final designation with at least eight penalty points could trigger a one-day trading halt.
• Annual penalty points total zero; reaching 10, including this case, could trigger a listing eligibility review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmuneOncia Therapeutics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261028900754), on October 28, 2026, and is solely responsible for the information contained therein.